Alimera Sciences Inc (ALIM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Alimera Sciences Inc (ALIM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9806
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alimera Sciences Inc (Alimera) is a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s products include Iluvien, an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabetic macular edema (DME) in patients who have been previously treated with corticosteroids and did not show any clinically significant increase in intraocular pressure (IOP). Iluvien is also prescribed for treatment of early-and late-stage diseases such as wet and dry age-related macular degeneration (AMD) and retinal vein occlusion. The company distributes its products in France, Austria, Portugal, the Czech Republic, Denmark, Finland, Germany, Spain, the UK and others. Alimera is headquartered in Alpharetta, Georgia, the US.

Alimera Sciences Inc (ALIM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alimera Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alimera Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Alimera Sciences Enters into Distribution Agreement with Horus Pharma 11
Alimera Sciences Enters into Distribution Agreement with Brill Pharma 12
Alimera Sciences Enters into Distribution Agreement with MEAgate 13
Alimera Sciences Enters into Distribution Agreement with SIFI for Iluvien 14
Alimera Sciences Enters into Distribution Agreement with Knight Therapeutics 15
Alimera Sciences Enters Into Distribution Agreement With Specialised Therapeutics For Iluvien 16
Equity Offering 17
Alimera Sciences Plans to Raise up to USD100 Million in Public Offering of Securities 17
Alimera Sciences Raises USD1.2 Million in Public Offering of Shares 18
Alimera Sciences Raises USD26.5 Million in Public Offering of Shares 19
Alimera Sciences Raises USD0.8 Million in Private Placement of Shares 21
Alimera Sciences Raises USD50 Million in Private Placement of Preferred Stock 22
Alimera Sciences Raises USD35 Million in Public Offering of Shares 24
Alimera Sciences Completes Private Placement Of Shares For US$37.5 Million 25
Alimera Sciences Completes Private Placement Of Units For US$40 Million 26
Acquisition 28
Alimera Sciences Mulls for Sale 28
Alimera Sciences Inc – Key Competitors 29
Alimera Sciences Inc – Key Employees 30
Alimera Sciences Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 05, 2018: Alimera Sciences reports third quarter 2018 results 32
Jul 31, 2018: Alimera Sciences Reports Second Quarter 2018 Results 34
May 02, 2018: Alimera Sciences Reports First Quarter 2018 Results 36
Feb 28, 2018: Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results 38
Nov 01, 2017: Alimera Sciences Reports Third Quarter 2017 Financial Results 40
Aug 02, 2017: Alimera Sciences Reports Second Quarter 2017 Financial Results 42
May 08, 2017: Alimera Sciences Reports First Quarter 2017 Financial Results 44
Mar 01, 2017: Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results 46
Corporate Communications 48
Jun 21, 2018: Alimera Sciences Names Mary T. Szela As Board Director 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alimera Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alimera Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Alimera Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alimera Sciences Enters into Distribution Agreement with Horus Pharma 11
Alimera Sciences Enters into Distribution Agreement with Brill Pharma 12
Alimera Sciences Enters into Distribution Agreement with MEAgate 13
Alimera Sciences Enters into Distribution Agreement with SIFI for Iluvien 14
Alimera Sciences Enters into Distribution Agreement with Knight Therapeutics 15
Alimera Sciences Enters Into Distribution Agreement With Specialised Therapeutics For Iluvien 16
Alimera Sciences Plans to Raise up to USD100 Million in Public Offering of Securities 17
Alimera Sciences Raises USD1.2 Million in Public Offering of Shares 18
Alimera Sciences Raises USD26.5 Million in Public Offering of Shares 19
Alimera Sciences Raises USD0.8 Million in Private Placement of Shares 21
Alimera Sciences Raises USD50 Million in Private Placement of Preferred Stock 22
Alimera Sciences Raises USD35 Million in Public Offering of Shares 24
Alimera Sciences Completes Private Placement Of Shares For US$37.5 Million 25
Alimera Sciences Completes Private Placement Of Units For US$40 Million 26
Alimera Sciences Mulls for Sale 28
Alimera Sciences Inc, Key Competitors 29
Alimera Sciences Inc, Key Employees 30
Alimera Sciences Inc, Subsidiaries 31

List of Figures
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alimera Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Alimera Sciences Inc (ALIM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NSK Ltd (6471):企業の財務・戦略的SWOT分析
    NSK Ltd (6471) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Vietnam Technological and Commercial Joint Stock Bank (TCB):企業の財務・戦略的SWOT分析
    Vietnam Technological and Commercial Joint Stock Bank (TCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the comp …
  • Steel Excel Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Steel Excel Inc (Steel Excel) is a provider of technology consulting and business development solutions. The company’s services comprise rogue pressure services, sun well services, black hawk energy services, functional fitness facilities, sports training, strength and conditioning gym facil …
  • Sandoz International GmbH:企業の戦略・SWOT・財務分析
    Sandoz International GmbH - Strategy, SWOT and Corporate Finance Report Summary Sandoz International GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Rhino Resource Partners LP:企業の戦略・SWOT・財務情報
    Rhino Resource Partners LP - Strategy, SWOT and Corporate Finance Report Summary Rhino Resource Partners LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Intrinsic Therapeutics Inc-医療機器分野:企業M&A・提携分析
    Summary Intrinsic Therapeutics Inc (Intrinsic) is a medical device company that develops medical devices for the treatment of lumbar disc herniations. The company offers prosthesis for partial anulus replacement following discectomy surgery; prosthesis for partial anulus replacement; and anular clos …
  • Huneed Technologies
    Huneed Technologies - Strategy, SWOT and Corporate Finance Report Summary Huneed Technologies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Callaway Golf Co (ELY):企業の財務・戦略的SWOT分析
    Callaway Golf Co (ELY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Dot Foods, Inc.:企業の戦略・SWOT・財務情報
    Dot Foods, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dot Foods, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Terumo Corporation:企業の戦略・SWOT・財務情報
    Terumo Corporation - Strategy, SWOT and Corporate Finance Report Summary Terumo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Physiomics Plc (PYC):製薬・医療:M&Aディール及び事業提携情報
    Summary Physiomics plc (Physiomics) is a computational systems biology services company. It offers Virtual Tumour, which optimizes the dosing and scheduling of oncology drugs in pre-clinical trials, cardiac toxicity services through its EasyAP, a Web-based simulation and analysis tool. It also offer …
  • APR Energy Ltd:企業の戦略的SWOT分析
    APR Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Asiana Airlines Inc.:企業の戦略・SWOT・財務分析
    Asiana Airlines Inc. - Strategy, SWOT and Corporate Finance Report Summary Asiana Airlines Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • CareCloud Corp:医療機器:M&Aディール及び事業提携情報
    Summary CareCloud Corp (CareCloud) is a healthcare technology company that offers cloud healthcare solutions. The company offers cloud-based healthcare IT solutions. It offers revenue cycle management, electronic health records, patient engagement, practice management, and others. CareCloud provides …
  • Nuo Therapeutics Inc (AURX):企業の財務・戦略的SWOT分析
    Nuo Therapeutics Inc (AURX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • RayBiotech Inc:医療機器:M&Aディール及び事業提携情報
    Summary RayBiotech Inc (RayBiotech) is a life science company that provides proteins, antibodies and immunological kits. The company's product categories include antibody arrays, glycobiology arrays, protein arrays, phosphorylation arrays, elisa, functional assays, antibodies and custom recombinant …
  • Norsk Hydro ASA:企業の戦略・SWOT・財務情報
    Norsk Hydro ASA - Strategy, SWOT and Corporate Finance Report Summary Norsk Hydro ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Anavex Life Sciences Corp (AVXL):企業の財務・戦略的SWOT分析
    Anavex Life Sciences Corp (AVXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • University of California Los Angeles:医療機器:M&Aディール及び事業提携情報
    Summary University of California Los Angeles (UCLA) a subsidiary of University of California, is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The university’s services include support services, campus services, gradua …
  • Great Portland Estates Plc (GPOR):企業の財務・戦略的SWOT分析
    Great Portland Estates Plc (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆